Prospective Investigation of Cardiovascular Risk Factors in Tumor Patients
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Adverse events (AEs) related to Cardio-oncology
研究概览
简要总结
In this study, prospective cohort study was used to collect the general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients who diagnosed cancer by pathology in National Cancer Center/ Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College from January 2018 to December 2020. This study intends to evaluate and screen the cardiovascular risk of tumor patients during antitumor therapy and to establish a model of cardiovascular risk assessment for tumor patients, providing clinical evidence for the prevention of cardiovascular disease risk associated with cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of malignant tumor by pathology or cytology
- •Age 18-80, KPS > 70
- •Epidemiological information, clinical diagnosis and treatment and key information of medication are not missing.
- •The liver and kidney function were in the normal range.
- •All selected patients signed informed consent.
排除标准
- •patients diagnosed with congenital heart disease, cardiomyopathy, heart failure, arrhythmia, myocardial ischemia and myocardial infarction within 6 months before enrollment.
- •Severe impairment of liver and kidney function.
- •Left ventricular ejection fraction < 50% by echocardiographic examination.
- •Diagnosis of more than one kind of tumor at the same time.
- •History of surgery and trauma within 3 months before enrollment.
- •Poor compliance
结局指标
主要结局
Adverse events (AEs) related to Cardio-oncology
时间窗: January 2018 to December 2020.
Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0) recorded by ECGs,UCGs and myocardial enzyme
次要结局
未报告次要终点
研究者
Fei Ma
Deputy director of medical oncology
Peking Union Medical College